Study on the clinical effect of phloroglucinol combined with somatostatin in the treatment of acute pancreatitis

Jiang Wentao; Yu Ruihang; Jia Hanjing

doi:10.3760/j.issn.1673-4777.2024.09.016

Abstract：Objective To investigate the clinical effect of phloroglucinol combined with somatostatin in the treatment of acute pancreatitis(AP).Methods Forty patients with AP who received treatment with combination therapy of phloroglucinol and somatostatin at the First Affiliated Hospital of Zhejiang Chinese Medicine University from January 2020 to November 2023 were included as the combination group,while 40 AP patients treated with somatostatin during the same period were included as the control group.Patients'data were collected for retrospective analysis.The clinical efficacy,clinical symptom relief time,the recovery time of blood amylase,inflammatory factors and blood amylase levels before and after treatment,adverse reaction incidence and mortality rate were compared between the two groups.Results The total effective rate of the combined group was higher than that of the control group[95.0％(38/40)vs 82.5％(33/40)],and the difference was statistically significant(x2=-3.181,P=0.001).The relief time of abdominal pain,nausea and vomiting,peritoneal irritation sign,and the recovery time of blood amylase in the combination group were shorter than those in the control group[4.00(2.00,4.25)d vs 6.00(5.00,7.00)d,4.00(2.00,5.00)d vs 6.00(5.00,7.00)d,2.00(2.00,3.00)d vs 4.00(3.00,5.00)d,4.00(2.00,6.00)d vs 6.00(2.75,9.00)d],and the differences were statistically significant(all P＜0.05).After treatment,the levels of tumor necrosis factor-α,interleukin-6,C-reactive protein,and blood amylase in two groups were all lower than before treatment,and those in combination group were lower than those in control group(all P＜0.05).There was no statistically significant difference in the incidence and mortality rates of adverse reactions between the two groups[10.0％(4/40)vs 15.0％(6/40),2.5％(1/40)vs 5.0％(2/40)](both P＞0.05).Conclusion Phloroglucinol combined with somatostatin is effective in the treatment of AP,which can effectively relieve clinical symptoms and inflammatory reaction,and will not cause serious adverse reactions.